(Q35753450)

10 August 2017

1 reference

title

Future directions in the treatment of Alzheimer's disease (English)

1 reference

10 August 2017

0 references

Roger Bullock

1

1 reference

PubMed ID

15102582

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

1 reference

10 August 2017

13

1 reference

10 August 2017

303-314

1 reference

10 August 2017

4

1 reference

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

10 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Plasticity and the spread of Alzheimer's disease-like changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Alzheimer's disease: genetic evidence points to a single pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

The role of presenilin cofactors in the gamma-secretase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Presenilins as therapeutic targets for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

A portrait of Alzheimer secretases--new features and familiar faces

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Alzheimer disease therapy: can the amyloid cascade be halted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Chemical andropause and amyloid-beta peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Anti-inflammatory drugs protect against Alzheimer disease at low doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Genetic epidemiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Protein misfolding and disease; protein refolding and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

The metallobiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Neuronal nicotinic receptors in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Towards Alzheimer's beta-amyloid vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Metabolic regulation of brain Abeta by neprilysin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Does diabetes protect or provoke Alzheimer's disease? Insights into the pathobiology and future treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Glucagon‐like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Tau is essential to beta -amyloid-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Divergent roles of GSK3 and CDK5 in APP processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

6-Ethyl-N,N'-bis(3-hydroxyphenyl)[1,3,5]triazine-2,4-diamine (RS-0466) enhances the protective effect of brain-derived neurotrophic factor on amyloid beta-induced cytotoxicity in cortical neurones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Acetylcholinesterase induces the expression of the beta-amyloid precursor protein in glia and activates glial cells in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Monoamine oxidase-B inhibition in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Inhibition of NF-kB Renders Cells more Vulnerable to Apoptosis Induced by Amyloid ß Peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

Stem cells for the treatment of neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.4.303

10.1517/13543784.13.4.303

21 January 2018

Identifiers

DOI

1 reference

release_aryenems5rbonpxvgrwqbyul3e

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/aryenems5rbonpxvgrwqbyul3e

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

15102582

1 reference

PubMed ID

15102582